About Us

eGenesis is a biotechnology company committed to using its multiplex gene editing and genome engineering platform to revolutionize the treatment of organ failure. We believe that cross-species transplantation has the potential to end waitlist mortality and remove supply as a barrier to transplant.

We have built a porcine genome engineering platform using advanced gene editing to create donor animals compatible for human transplantation. Our approach focuses on three classes of genetic edits to address retroviral risk and improve immunologic as well as molecular compatibility with human recipients.